SK116894A3 - Mixture for treatment of fibrotic disordes - Google Patents

Mixture for treatment of fibrotic disordes Download PDF

Info

Publication number
SK116894A3
SK116894A3 SK1168-94A SK116894A SK116894A3 SK 116894 A3 SK116894 A3 SK 116894A3 SK 116894 A SK116894 A SK 116894A SK 116894 A3 SK116894 A3 SK 116894A3
Authority
SK
Slovakia
Prior art keywords
beta
ftr
composition
factor
wound
Prior art date
Application number
SK1168-94A
Other languages
English (en)
Slovak (sk)
Inventor
Mark W J Ferguson
Mamta Shah
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of SK116894A3 publication Critical patent/SK116894A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1168-94A 1992-03-28 1993-03-22 Mixture for treatment of fibrotic disordes SK116894A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929206861A GB9206861D0 (en) 1992-03-28 1992-03-28 Wound healing and treatment of fibrotic disorders
PCT/GB1993/000586 WO1993019769A1 (fr) 1992-03-28 1993-03-22 Guerison de plaies et traitement de troubles fibrotiques

Publications (1)

Publication Number Publication Date
SK116894A3 true SK116894A3 (en) 1995-02-08

Family

ID=10713078

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1168-94A SK116894A3 (en) 1992-03-28 1993-03-22 Mixture for treatment of fibrotic disordes

Country Status (19)

Country Link
US (1) US6331298B1 (fr)
EP (1) EP0646012B1 (fr)
JP (2) JP3919212B2 (fr)
AT (1) ATE230605T1 (fr)
AU (1) AU673161B2 (fr)
BR (1) BR9306226A (fr)
CA (1) CA2131383C (fr)
CZ (1) CZ236694A3 (fr)
DE (1) DE69332624T2 (fr)
DK (1) DK0646012T3 (fr)
ES (1) ES2189790T3 (fr)
GB (1) GB9206861D0 (fr)
HU (1) HUT68905A (fr)
NO (1) NO943466L (fr)
NZ (1) NZ249937A (fr)
PT (1) PT646012E (fr)
RU (1) RU94042387A (fr)
SK (1) SK116894A3 (fr)
WO (1) WO1993019769A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
EP0670733A1 (fr) * 1993-09-29 1995-09-13 Alcon Laboratories, Inc. Compositions contenant des facteurs de croissance et des agents antiplastiques
JP4083794B2 (ja) * 1994-03-29 2008-04-30 レノボ・リミテッド 創傷の治癒
GB2288118A (en) * 1994-03-29 1995-10-11 Univ Manchester Wound healing composition
US5621093A (en) * 1995-06-06 1997-04-15 Anika Research, Inc. Steam-sterilizing solid hyaluronic acid
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
PT941108E (pt) * 1996-12-04 2003-01-31 Renovo Ltd Cicatrizacao de feridas e tratamento da fibrose
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
CN101484575B (zh) * 2005-06-08 2013-10-02 森托科尔公司 用于眼变性的细胞疗法
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
GB0604938D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0604964D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
AU2007244675A1 (en) 2006-04-28 2007-11-08 Lifescan, Inc. Differentiation of human embryonic stem cells
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
GB0617816D0 (en) * 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression
US8247384B2 (en) 2006-11-15 2012-08-21 Coda Therapeutics, Inc. Methods and compositions for wound healing
EP2126045A4 (fr) * 2007-01-30 2010-05-26 Univ Georgia Cellules mesodermiques precoces, une population stable de cellules mesendodermiques qui a une utilite pour la generation de lignees endodermiques et mesodermiques et de cellules migratoires multipotentes (mmc)
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
BRPI0813787A2 (pt) 2007-07-01 2014-10-07 Lifescan Inc Cultura de célula-tronco pluripotente isolada
AU2008273813B2 (en) * 2007-07-12 2013-06-13 Compugen Ltd. Bioactive peptides and method of using same
CA2693156C (fr) 2007-07-18 2018-03-06 Alireza Rezania Differenciation de cellules souches embryonnaires humaines
RU2473685C2 (ru) 2007-07-31 2013-01-27 Лайфскен, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
ATE523585T1 (de) * 2007-11-27 2011-09-15 Lifescan Inc Differenzierung menschlicher embryonaler stammzellen
CA2710388A1 (fr) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Utilisation de polynucleotides anti-connexine pour le traitement de cicatrices anormales ou excessives
CA2710386A1 (fr) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Dispositifs medicaux ameliores
US20110217313A1 (en) * 2007-12-21 2011-09-08 Becker David L Treatment of orthopedic conditions
KR20190057164A (ko) 2008-02-21 2019-05-27 얀센 바이오테크 인코포레이티드 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
JP5734183B2 (ja) * 2008-06-30 2015-06-17 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の分化
CA2728930C (fr) 2008-07-07 2014-12-09 Laboratoire Medidom S.A. Pansement favorisant la cicatrisation et abaissant la temperature
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
CN102165058B (zh) 2008-07-25 2015-07-01 佐治亚大学研究基金会 中胚层来源的ISL 1+多潜能细胞(IMPs)的组合物、心外膜祖细胞(EPCs)和多潜能CXCR4+CD56+细胞(C56Cs)及其使用方法
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
RU2528861C2 (ru) * 2008-10-31 2014-09-20 Сентокор Орто Байотек Инк. Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток
CN102272291B (zh) 2008-10-31 2018-01-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
BRPI0920956A2 (pt) 2008-11-20 2015-08-18 Centocor Ortho Biotech Inc Cultura de células-tronco pluripotentes em microveículos
RU2547925C2 (ru) * 2008-11-20 2015-04-10 Сентокор Орто Байотек Инк. Способы и композиции для закрепления и культивирования клеток на плоских носителях
GB2485112B (en) * 2009-07-20 2014-02-26 Janssen Biotech Inc Differentiation of human embryonic stem cells
SG177416A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
WO2011011300A2 (fr) 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Différentiation de cellules souches embryonnaires humaines
AR078805A1 (es) * 2009-10-29 2011-12-07 Centocor Ortho Biotech Inc Celulas madre pluripotentes
DE202009017772U1 (de) * 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
RU2701335C2 (ru) 2009-12-23 2019-09-25 Янссен Байотек, Инк. Способ получения популяции панкреатических эндокринных клеток, соэкспрессирующих nkx6.1 и инсулин, и способ лечения диабета
ES2633648T3 (es) 2009-12-23 2017-09-22 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
CA2791476C (fr) 2010-03-01 2020-06-30 Janssen Biotech, Inc. Procedes de purification de cellules issues de cellules souches pluripotentes
RU2663339C1 (ru) 2010-05-12 2018-08-03 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
WO2012021698A2 (fr) 2010-08-12 2012-02-16 Janssen Biotech, Inc. Traitement du diabète au moyen de cellules précurseurs endocrines pancréatiques
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
PL2611910T3 (pl) 2010-08-31 2018-06-29 Janssen Biotech, Inc Różnicowanie ludzkich embrionalnych komórek macierzystych
EP2611907B1 (fr) 2010-08-31 2016-05-04 Janssen Biotech, Inc. Différenciation de cellules souches pluripotentes
US9404087B2 (en) 2010-12-15 2016-08-02 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
EP2794857A4 (fr) 2011-12-22 2015-07-08 Janssen Biotech Inc Différenciation de cellules souches embryonnaires humaines en cellules positives pour l'insuline hormonales individuelles
CA2866590A1 (fr) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Milieux definis pour le developpement et la preservation des cellules souches pluripotentes
EP3450542B1 (fr) 2012-06-08 2021-09-01 Janssen Biotech, Inc. Différenciation de cellules souches embryonnaires humaines en cellules endocrines pancréatiques
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
CA2896658C (fr) 2012-12-31 2021-06-22 Janssen Biotech, Inc. Differenciation de cellules souches embryonnaires humaines en cellules endocrines pancreatiques au moyen de regulateurs de hb9
RU2658488C2 (ru) 2012-12-31 2018-06-21 Янссен Байотек, Инк. Способ получения клеток, экспрессирующих маркеры, характерные для панкреатических эндокринных клеток
WO2014106141A1 (fr) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Mise en suspension et agrégation de cellules pluripotentes humaines pour la différenciation en cellules endocrines du pancréas
EP2972193B1 (fr) 2013-03-13 2019-12-18 University Of Miami Procédé pour isoler et purifier les microvésicules de surnageants de culture cellulaire et fluides biologiques
KR102162138B1 (ko) 2014-05-16 2020-10-06 얀센 바이오테크 인코포레이티드 췌장 내분비 세포에서 mafa 발현을 향상시키기 위한 소분자의 용도
CN114010788A (zh) 2014-08-22 2022-02-08 奥克兰联合服务有限公司 通道调节剂
WO2017094001A1 (fr) 2015-11-30 2017-06-08 Kadimastem Ltd Procédés de différenciation et de purification de cellules endocrines pancréatiques
RU2018131123A (ru) 2016-02-17 2020-03-17 Новартис Аг Антитела к tgf-бета2
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
JP7531887B2 (ja) 2020-07-31 2024-08-13 学校法人関西医科大学 ＴＧＦ－βを含む組織の線維化抑制剤
IL300393A (en) 2020-08-21 2023-04-01 Univ Miami Preparations and treatment methods using microvesicles from mesenchymal stem cells derived from bone marrow
WO2023205158A1 (fr) 2022-04-19 2023-10-26 University Of Miami Compositions avec microvésicules pour la prévention et le traitement de la maladie du greffon contre l'hôte

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
GB8823649D0 (en) 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
IE61346B1 (en) 1988-11-02 1994-11-02 Genentech Inc A permeable material to fit around the teeth or gums of a mammal
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
WO1991010727A1 (fr) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibiteurs de facteurs regulateurs cellulaires
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing

Also Published As

Publication number Publication date
PT646012E (pt) 2003-03-31
EP0646012A1 (fr) 1995-04-05
DE69332624T2 (de) 2003-10-02
US6331298B1 (en) 2001-12-18
WO1993019769A1 (fr) 1993-10-14
EP0646012B1 (fr) 2003-01-08
BR9306226A (pt) 1996-12-03
NO943466D0 (no) 1994-09-16
HUT68905A (en) 1995-08-28
DK0646012T3 (da) 2003-03-03
ES2189790T3 (es) 2003-07-16
NZ249937A (en) 1996-09-25
ATE230605T1 (de) 2003-01-15
JP2005290009A (ja) 2005-10-20
JPH07505378A (ja) 1995-06-15
AU673161B2 (en) 1996-10-31
CZ236694A3 (en) 1995-04-12
RU94042387A (ru) 1996-11-10
NO943466L (no) 1994-09-16
DE69332624D1 (de) 2003-02-13
CA2131383C (fr) 2002-07-16
GB9206861D0 (en) 1992-05-13
CA2131383A1 (fr) 1993-10-14
JP3919212B2 (ja) 2007-05-23
HU9402771D0 (en) 1995-01-30
AU3762393A (en) 1993-11-08

Similar Documents

Publication Publication Date Title
SK116894A3 (en) Mixture for treatment of fibrotic disordes
ES2136618T5 (es) Curacion de heridas.
DE69807710T2 (de) Verwendung von Latenz Assoziierten Peptiden in der Herstellung eines Medikaments zur Verbesserung der Wundheilung.
CN1814279A (zh) 重组人碱性成纤维细胞生长因子凝胶剂及其制备方法
KR20080031394A (ko) Ｔｇｆ-베타 수퍼패밀리 구성원을 포함하는 약학 조성물
SK281461B6 (sk) Kolagénový prípravok na riadené uvoľňovanie účinných látok
JP4102437B2 (ja) アクチビンおよびインヒビン刺激因子を含有する医薬組成物
RU2248216C2 (ru) Композиция и способ увеличения количества стволовых клеток и/или гематопоэтических клеток-предшественников в циркуляции в периферической крови млекопитающих
EP2572724B1 (fr) Traitement de fibroses et de maladies du foie
EP2737895A1 (fr) Microparticules avec EGF, procédé de préparation et d'utilisation
CN115364097B (zh) 一种含杂原子环丁烷取代基的吡啶酮衍生物的应用
JP5860406B2 (ja) 徐放性医薬組成物
KR20240117782A (ko) 켈로이드 치료를 위한 피부 패치와 주사 치료제 조성물
JP2002528384A (ja) ペントキシフィリン及び抗サイトカインベースの組成物
EP4259176A2 (fr) Compositions et méthodes de traitement de plaies
CN115518145A (zh) 一种用于修复皮肤缺损、祛痘和/或除皱的药物
US20050025743A1 (en) Method of preventing adhesions wtih ifn-upsilon
JP2688733B2 (ja) 消化管粘膜障害の予防及び治療剤
Nies et al. Combination containing growth factors and polyelectrolytes
WO2002072016A2 (fr) Procede de prevention d'adherences par ifn-¿y?